Mosaic ImmunoEngineering (CPMV) Deferred Taxes (2010 - 2019)
Mosaic ImmunoEngineering (CPMV) posted quarterly Deferred Taxes of -$26078.0 for Q2 2019, down 125.0% year-over-year from $104312.0 in Q2 2018, and down 125.0% quarter-over-quarter from $104312.0 in Q2 2018.
Mosaic ImmunoEngineering (CPMV) Deferred Taxes (2010 - 2019) Analysis & Trends
Mosaic ImmunoEngineering's Deferred Taxes history runs 4 years deep, the most recent figure standing at -$26078.0 for Q2 2019.
- In Q2 2019, Deferred Taxes fell 125.0% year-over-year to -$26078.0; the TTM figure through May 2019 stood at $4.3 million (down 46.67% YoY), while the FY2020 annual figure was -$26078.0, changed 0.0% from the prior year.
- Deferred Taxes for Q2 2019 stood at -$26078.0, down from $104312.0 in the prior quarter.
- The five-year high for Deferred Taxes was $104312.0 in Q2 2018, with the low at -$26078.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 2.66 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2019 | -26,078.00 |
| May 31, 2018 | 104,312.00 |
| May 31, 2011 | 4.27 Mn |
| Feb 28, 2011 | 3.78 Mn |
| Nov 30, 2010 | -562,067.00 |
| Aug 31, 2010 | -1.33 Mn |